8-K: NeuroBo's DA-1241 Shows Promising Results in Combination Therapy for Liver Disease

Pre-clinical data suggests that NeuroBo's DA-1241, when combined with semaglutide, demonstrates improved liver fibrosis and hepatoprotective effects in MASH models compared to either treatment alone.

Summary

• NeuroBo Pharmaceuticals announced pre-clinical data indicating that their drug candidate, DA-1241, a GPR119 agonist, shows enhanced benefits when used in combination with semaglutide (Wegovy) for treating metabolic dysfunction-associated steatohepatitis (MASH).
• The combination therapy demonstrated improved liver fibrosis and additive hepatoprotective effects in pre-clinical MASH models compared to either treatment alone.
• The data will be presented at the EASL Congress 2024 in Milan, Italy, from June 5-8.
• The study used GAN diet-induced obese mice with biopsy-confirmed MASH, and another study used mice with CCl4 induced liver fibrosis.
• In the GAN DIO-MASH model, the combination therapy led to a 2-point improvement in NAS in 80% of mice, compared to 21% with each monotherapy.
• In the CCl4 model, the combination therapy reduced collagen-positive area to 6.05%, compared to 17.8% and 17.1% with DA-1241 and semaglutide alone, respectively.
• NeuroBo is currently conducting a Phase 2a clinical trial of DA-1241 in MASH, with top-line data expected in the fourth quarter of this year.

Sentiment

Score: 8

Explanation: The document presents very positive pre-clinical results for a combination therapy, suggesting a potential breakthrough in MASH treatment. The company is also progressing with clinical trials, which adds to the positive outlook.

Positives

• The combination of DA-1241 and semaglutide shows synergistic effects in reducing liver fibrosis and inflammation in pre-clinical models.
• DA-1241 has shown potential in reducing hepatic steatosis, inflammation, and fibrosis, while also improving glucose control in pre-clinical studies.
• DA-1241 was well tolerated in Phase 1a and 1b trials in healthy volunteers and those with type 2 diabetes.
• The combination therapy demonstrated more than additive effects on metabolic, biochemical, and histological endpoints in GAN DIO-MASH mice.
• The combination therapy fully restored the gene expression of Hhip, a suppressor of hepatic stellate cell activation, in the CCl4 model.

Negatives

• While semaglutide significantly reduced body weight, DA-1241 was weight-neutral in the GAN DIO-MASH model.
• There was no additional weight loss in the combination group compared to semaglutide alone in both models.

Risks

• The results are based on pre-clinical data and may not translate directly to human clinical trials.
• The company's ability to execute its commercial strategy and obtain regulatory approval is subject to risks and uncertainties.
• There are risks associated with the cooperation of contract manufacturers, clinical study partners, and others involved in the development of NeuroBo's product candidates.
• Potential negative interactions between the product candidates and other products used in combination therapy are a risk.
• The company's ability to initiate and complete clinical trials on a timely basis and recruit subjects is subject to risks.

Future Outlook

NeuroBo anticipates reporting top-line data from both parts of the ongoing Phase 2a clinical trial in MASH in the fourth quarter of this year.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of NeuroBo, stated that the data further strengthens the pre-clinical evidence that DA-1241's activation of GPR119 has therapeutic potential for the reduction of hepatic steatosis, inflammation, fibrosis, and improved glucose control.
• NeuroBo believes the unique mechanism of DA-1241, targeting the inflammation associated with MASH, will translate into a safe and effective treatment for this disease.

Industry Context

The announcement highlights the growing interest in combination therapies for MASH, a complex disease with limited treatment options. The use of a GPR119 agonist in combination with a GLP1R agonist like semaglutide is a novel approach that could potentially offer improved outcomes for patients with MASH.

Comparison to Industry Standards

• The combination of a GPR119 agonist with a GLP-1 agonist is a novel approach, as most current treatments focus on single-target mechanisms.
• Companies like Madrigal Pharmaceuticals (Resmetirom) and Viking Therapeutics (VK2809) are also developing treatments for MASH, but their mechanisms of action differ from NeuroBo's approach.
• The results of the combination therapy in reducing liver fibrosis and inflammation appear promising compared to monotherapies, but further clinical trials are needed to confirm these findings in humans.
• The 2-point improvement in NAS in 80% of mice with the combination therapy is a significant result compared to the 21% improvement with monotherapies, suggesting a potential advantage of the combination approach.

Stakeholder Impact

• Shareholders may view the positive pre-clinical data as a positive development for the company's drug pipeline.
• Employees may be encouraged by the progress of the company's research and development efforts.
• Patients with MASH may see this as a potential new treatment option in the future.
• The company's partners and collaborators may be encouraged by the positive results.

Next Steps

• NeuroBo will present the pre-clinical data at the EASL Congress 2024.
• The company will continue to enroll patients in Part 2 of their Phase 2a clinical trial of DA-1241 in MASH.
• NeuroBo expects to report top-line data from both parts of the ongoing Phase 2a clinical trial in MASH in the fourth quarter of this year.

Key Dates

Keywords

MASH, DA-1241, semaglutide, GPR119 agonist, liver fibrosis, hepatoprotective, clinical trial, metabolic dysfunction, inflammation, steatosis